NEWARK, Calif., June 17, 2019 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ:PTGX) today announced that David Liu, Ph.D., Chief Scientific Officer and
Head of Research and Development, will provide a corporate overview
at the BMO 2019 Prescription for Success Healthcare Conference in
New York.
Presentation details:
Event: BMO 2019 Prescription for Success Healthcare Conference
Date: Tuesday, June 25, 2019
Time: 3:40 p.m. EDT
A live and archived webcast of the presentation can be accessed
by visiting the Investors page of the Protagonist Therapeutics
website at http://investors.protagonist-inc.com.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based drugs to transform existing
treatment paradigms for patients with significant unmet medical
needs. PTG-300 is an injectable hepcidin mimetic in development for
the treatment of anemia and iron overload related rare blood
diseases. PTG-300 is currently in a global Phase 2 study in
beta-thalassemia. PTG-200 is an oral, gut-restricted interleukin-23
receptor specific antagonist peptide in development for the
treatment of inflammatory bowel disease. The Company has a
worldwide license and collaboration agreement with Janssen Biotech
for the clinical development of PTG-200 and a Phase 2 study in
Crohn's disease is expected. PN-943, currently in a Phase 1 study,
is an oral, gut-restricted alpha-4-beta-7 integrin specific
antagonist peptide in development for the treatment of inflammatory
bowel disease.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-bmo-2019-prescription-for-success-healthcare-conference-300867973.html
SOURCE Protagonist Therapeutics, Inc.